Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

COCP vs IBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IBIO Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 4–3 Matrix Metrics)

IBIO Overall Winner 6-Pillar Tally: COCP 0 – 4 IBIO (2 Tie) Matrix Metrics: COCP 3 – 4 IBIO

As of Nov 16, 2026, iBio, Inc. (IBIO) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCP carries a Unified Composite Score of 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin), whereas IBIO carries 46.0/100 (HOLD) at $0.72 (N/M Forward P/E, -3025.6% operating margin).

  • Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. IBIO 46.0/100 HOLD), IBIO captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-3025.6% vs. -3063.6% operating margin) and revenue trajectory (+975.0% vs. +26.9% YoY).
  • Technical & Structure Timing Caution: COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3); meanwhile IBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About COCP vs IBIO
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
TTM Revenue $330,000
Forward P/E N/M
Beta / 30D Vol 1.04β · 54% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $1.00 · SMA50: $1.08
IBIO NASDAQ Head-to-Head Winner
iBio, Inc. Common Stock
Pharmaceutical Preparations
$0.72
-2.04% 1D
Market Cap $53.7M
TTM Revenue $1.1M
Forward P/E N/M
Beta / 30D Vol 2.07β · 89% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.5%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $0.78 · SMA50: $0.97

6-Pillar Scorecard Institutional Category Breakdown (COCP 0 – 4 IBIO)

Columns: Metric · COCP · IBIO
1. Valuation Multiples IBIO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 49.7x 7.8x
2. Growth & Scale IBIO
Revenue Growth (YoY) +26.9% +975.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $330,000 $1.1M
Market Cap $19.6M $53.7M
3. Profitability & Quality IBIO
Gross Margin N/A 100.0%
Operating Margin -3063.6% -3025.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -311.7% -51.8%
4. Balance Sheet & Cash Flow IBIO
Cash Generation (TTM) -$7.6M -$22M
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.3M Net Cash $45M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: COCP (3) vs IBIO (4)
Institutional Metric COCP IBIO Criterion Row Edge
Market Capitalization
Scale
$19.6M $53.7M Larger Scale IBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+26.9% +975.0% Higher Growth IBIO
Operating Margin (TTM)
Profitability
-3063.6% -3025.6% Higher Margin IBIO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-311.7% -51.8% Higher ROE IBIO
52-Week Range Position
Momentum
19% ($1–$2) 1% ($1–$4) Stronger Trend COCP
Beta / 30D Volatility
Risk Regime
1.04β · 54% Vol 2.07β · 89% Vol Lower Realized Risk COCP
Unified Institutional Score
Composite Signal
47.1 / 100 (HOLD) 46.0 / 100 (HOLD) Higher Composite COCP
Trailing 12M Revenue (USD)
Operating Scale
$330,000 $1.1M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 49.7x EV/Rev N/M PEG · 7.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.6M ($3.3M Net Cash) -$22M ($45M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCP +4.45 pp
COCP: -2.01% · IBIO: -6.46%
3M Horizon COCP +43.12 pp
COCP: -7.45% · IBIO: -50.57%
6M Horizon COCP +34.22 pp
COCP: -15.3% · IBIO: -49.52%
1Y Horizon COCP +34.71 pp
COCP: -2.96% · IBIO: -37.67%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period COCP Revenue IBIO Revenue COCP Op. Margin IBIO Op. Margin Margin Leader
FY2018 N/A $0M N/A -3204.3% IBIO
FY2019 $10M $0M -737.4% -782.4% COCP
FY2020 $0M $0M -476.0% -854.9% COCP
FY2021 N/A $0M N/A -1312.1% IBIO
FY2022 N/A $0M N/A -1576.3% IBIO
FY2024 N/A $0M N/A -7392.9% IBIO
FY2025 N/A $0M N/A -4650.5% IBIO
FY2026 N/A $0M N/A -35141.0% IBIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
COCP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
COCP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $19.6M market capitalization and -3063.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $53.7M market capitalization and -3025.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ COCP vs IBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, iBio, Inc. (IBIO) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCP carries a Unified Composite Score of 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin), whereas IBIO carries 46.0/100 (HOLD) at $0.72 (N/M Forward P/E, -3025.6% operating margin). Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. IBIO 46.0/100 HOLD), IBIO captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-3025.6% vs. -3063.6% operating margin) and revenue trajectory (+975.0% vs. +26.9% YoY). Technical & Structure Timing Caution: COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3); meanwhile IBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IBIO leads the Growth & Scale pillar: COCP posts +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin), compared with IBIO at +975.0% YoY revenue growth and +0.0% YoY earnings growth on $1.1M TTM revenue (100.0% gross margin, -3025.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), COCP cumulative revenue shifted N/A while IBIO shifted N/A. In operating R&D and SG&A reinvestment, COCP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBIO.

IBIO screens cheaper on headline valuation multiples. COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin), whereas IBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCP (-311.7% ROE) versus IBIO (-51.8% ROE) capital efficiency.

In options market volatility and institutional positioning, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 54% Vol realized risk). By comparison, IBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 89% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.